---
title: Atheln, Inc. vs CMIC HOLDINGS Co., Ltd.
slug_a: athelnbiomed
slug_b: cmicgroup
site: cro
review_signal_gate: closed
canonical_path: /compare/athelnbiomed/cmicgroup
---

# Atheln, Inc. vs CMIC HOLDINGS Co., Ltd.

Side-by-side profile data from each company listing on this directory.

## Atheln, Inc.

- Profile: [/companies/athelnbiomed](/companies/athelnbiomed)

Atheln, Inc. — Atheln provides customized strategic and operational consulting across product development, CMC, nonclinical, clinical, regulatory, and commercial services for pharma, biotech, and medtech clients.

Services: 11. Modalities: 5. Indications: 1. Locations: 0. Certifications: 0. The strongest documented coverage currently appears in services (11).

### Services

- Clinical Trial Services
- Clinical Operations
- Biostatistics & Statistical Programming
- Medical Writing
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- Translational Research

### Modalities

- Small Molecule
- Biologics (Other)
- Oligonucleotide
- Peptide
- Radiopharmaceutical

### Indications

- Ophthalmology

### Phases

- Discovery
- Preclinical (General)
- Preclinical (IND-Enabling)
- Phase I
- Phase II
- Phase III
- Phase IV

### Sourcing models

- Full-Service Outsourcing (FSO)
- Functional Service Provider (FSP)

## CMIC HOLDINGS Co., Ltd.

- Profile: [/companies/cmicgroup](/companies/cmicgroup)

CMIC HOLDINGS Co., Ltd. — CMIC HOLDINGS is a Japanese healthcare group whose Pharmaceutical Solutions cover consulting, non-clinical CRO, CRO, CDMO, SMO and CSO services. The group says it supports pharmaceutical companies across the value chain from non-clinical stages through post-marketing.

Services: 11. Modalities: 0. Indications: 0. Locations: 0. Certifications: 0. The strongest documented coverage currently appears in services (11).

### Services

- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy

### Modalities

- Data not yet provided.

### Indications

- Data not yet provided.

### Phases

- Preclinical (General)
- Phase I
- Phase II
- Phase III
- Phase IV

### Sourcing models

- Full-Service Outsourcing (FSO)